Richard W. Pascoe was named Chief Executive Officer of Histogen Inc. in January of 2019. Mr. Pascoe joined the company following the merger of Apricus Biosciences Inc. and Seelos Therapeutics, Inc. Mr. Pascoe was the Chief Executive Officer of Apricus from March 2013 until joining Histogen. Prior to Apricus, Mr. Pascoe was with Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics, Inc.) where he served as the Chief Executive Officer.
Prior to joining Somaxon in 2008, Mr. Pascoe held a series of senior management roles to include Chief Operating Officer at ARIAD Pharmaceuticals, Inc. (acquired by Takeda Inc.) and Senior Vice President of Neuroscience Division at King Pharmaceuticals, Inc. (acquired by Pfizer Inc.). Prior to King, Mr. Pascoe held commercial roles in the hospital pharmaceutical and medical device groups at Medco Research, Inc. (acquired by King), COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals Inc.), and B. Braun Interventional.
Mr. Pascoe is a member of the board of directors of KemPharm, Inc., where he serves as lead independent director, chair of the audit committee and member of the compensation committee. He also serves as a member of the board of directors of Seelos Therapeutics, Inc. He is the chairman of the board of directors of Biocom, California’s leading advocate for the life sciences industry, and a member of the Johnny Mac Soldiers Fund, a charity for military veterans.
Mr. Pascoe served on active duty as a commissioned officer with the U.S. Army’s 24th Infantry Division with one combat tour in Iraq where he earned several awards and decorations including the Bronze Star Medal. He is a graduate of the United States Military Academy at West Point where he received a B.S. degree in Leadership. Mr. Pascoe was appointed as the Civilian Aide to the Secretary of the Army for Southern California in 2017, where he serves as a liaison between the Secretary of the Army and the local community.